The progression of severe aplastic anemia to hypoplastic leukemia in a long-term observation after the administration of pegylated rHuMGDF

Main Article Content

Maho Ishikawa *
Akira Matsuda
Daisuke Okamura
Tomoya Maeda
Nobutaka Kawai
Norio Asou
Masami Bessho
(*) Corresponding Author:
Maho Ishikawa |


Thrombopoietin (TPO) is a critical regulator of hematopoiesis. We previously reported that a severe aplastic anemia (SAA) who received a short-term administration of pegylated recombinant human megakaryocyte growth and development factor (rHuMGDF). A trilineage hematologic response was induced, however the patient was diagnosed with leukemia after nine years and eight months from administration of rHuMGDF. In recent reports, somatic mutations in myeloid cancer candidate genes were present in one-third of the AA. A mutant clone may be expanded by rHuMGDF in our patient. The long-term safety of patients treated with TPO and eltrombopag remains unknown. Careful observations are warranted hereafter.

Downloads month by month


Download data is not yet available.

Article Details

Author Biography

Maho Ishikawa, Department of Hemato-Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama